A new report produced by a business and market research company (Vertical Edge Limited, London, UK) has predicted that sales of Regeneron’s Eylea (aflibercept) will… Read More »Eylea is forecast to attain revenues of US$4,475 million and overtake Lucentis revenues by 2022
Results of a clinical trial into the treatment of non-infectious uveitis, supported by Santen Inc. (Osaka, Japan), have reported that over 70% of the patients… Read More »Reformulated rapamycin (sirolimus) shows promising 12-month results in treatment of uveitis
Research conducted at the University Hospital in Bern Switzerland suggests that scleral changes may occur in patients following repeated intravitreal injections of anti-VEGF agents in… Read More »Scleral thinning following intravitreal anti-VEGF injections
A research team from the Hebrew University of Jerusalem recently demonstrated that the same part of the visual cortex activated in sighted individuals when reading… Read More »Congenitally blind patients reading “through sound” show activation of visual cortex in the brain including response to colour.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced the receipt of European Union approval for aflibercept (marketed as Eylea) for the treatment of visual impairment due… Read More »Regeneron Inc. announces receipt of Eylea’s EU approval for macular edema secondary to Retinal Vein Occlusion
The US National Eye Institute (NEI) will be sponsoring the first gene therapy trials in X-linked retinoschisis, led by NEI Director Dr. Paul Sieving M.D.,… Read More »First X-linked retinoschisis gene therapy trial launches with support of the US NEI
Research conducted at the Rutgers New Jersey Medical School, Newark and published in the American Journal of Ophthalmology, has highlighted a statistical association between scholarly… Read More »Research on outcomes of medical malpractice litigation suggest expert witnesses with higher levels of scholarly impact may have an edge
A research team from the Hebrew University of Jerusalem recently demonstrated that the same part of the visual cortex activated in sighted individuals when reading… Read More »Congenitally blind patients reading “through sound” show activation of visual cortex in the brain including response to colour.
Pfenex Inc., a clinical stage biotech company based in San Diego, California, has announced execution of an agreement with Hospira Inc. (Illinois) to exclusively develop… Read More »Lucentis biosimilar advances through collaboration between Pfenex Inc. and Hospira Inc.
Research, published in the New England Journal of Medicine (NEJM), has concluded that aflibercept is more effective than bevacizumab and ranibizumab at improving vision for… Read More »NEJM research recommends use of aflibercept (Eylea) as first-line therapy in patients with a VA of 20/50 or worse